Pharmacokinetics and preliminary safety of single-dose oral fluralaner at 10 and 25 mg/kg in healthy horses revealed no adverse reactions
American Journal of Veterinary Research · 2025
DOI: 10.2460/ajvr.25.06.0200 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2025. Verfasst von Jessica M Morgan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA. Hauptthemen laut MEDLINE: Isoxazoles, Acaricides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To determine the safety and pharmacokinetics of a single dose of the oral ectoparasiticide fluralaner at 10 and 25 mg/kg in healthy horses.
Methods
12 clinically healthy university-owned horses, 9 to 17 years of age, were administered a single oral dose of fluralaner at 10 or 25 mg/kg. Physical examinations, neurological examinations, plasma samples, hematology and biochemistry panels, and skin biopsies were collected throughout the 84-day trial period. Fluralaner concentrations were measured in plasma and skin by liquid chromatography-tandem mass spectrometry, and pharmacokinetics were evaluated in plasma using a noncompartmental analysis.
Results
After oral administration at 10 or 25 mg/kg, fluralaner was detected in all horses. Fluralaner was detectable in plasma for a mean of 42 ± 16.6 or 30.3 ± 3.61 days at the 10- and 25-mg/kg doses, respectively. Pharmacokinetic results for 10- and 25-mg/kg doses, respectively, were a terminal half-life of 6.03 ± 3.87 or 3.02 ± 0.25 days, maximum concentration of 162.1 ± 21.6 or 403.3 ± 129.5 ng/mL, and time to maximal concentration of 0.42 ± 0.14 or 0.64 ± 0.29 days. Skin concentrations in horses administered 25 mg/kg peaked 1 day postadministration at a median of 2.30 μg/g (IQR, 1.31 to 8.23 μg/g) and remained detectable to day 84. No adverse effects of fluralaner were detected.
Conclusions
Fluralaner is absorbed orally at 10 and 25 mg/kg in healthy horses and appears to be safe and well tolerated. Clinical Relevance Fluralaner's persistence in skin and plasma after oral administration has potential as a treatment for select ectoparasites in the horse, although further study is needed to determine the appropriate dose and dose interval.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA.
- Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California-Davis, Davis, CA.
- K. L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California-Davis, Davis, CA.
ORCID-Profile: Jessica M Morgan, Jennifer M Cassano, Stephen D White
Zitieren
APA
Morgan, J. M., Gentille, S. R., Goyette, F. D., Lehman, M. L., Boss, A. L., Cassano, J. M., Knych, H. K., & White, S. D. (2025). Pharmacokinetics and preliminary safety of single-dose oral fluralaner at 10 and 25 mg/kg in healthy horses revealed no adverse reactions. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.25.06.0200
Vancouver
Morgan JM, Gentille SR, Goyette FD, Lehman ML, Boss AL, Cassano JM, et al. Pharmacokinetics and preliminary safety of single-dose oral fluralaner at 10 and 25 mg/kg in healthy horses revealed no adverse reactions. American Journal of Veterinary Research. 2025. doi:10.2460/ajvr.25.06.0200
BibTeX
@article{Morgan2025,
author = {Morgan, Jessica M and Gentille, Samantha R and Goyette, Francesca D and Lehman, Mallory L and Boss, Amber L and Cassano, Jennifer M and Knych, Heather K and White, Stephen D},
title = {Pharmacokinetics and preliminary safety of single-dose oral fluralaner at 10 and 25 mg/kg in healthy horses revealed no adverse reactions},
journal = {American Journal of Veterinary Research},
year = {2025},
doi = {10.2460/ajvr.25.06.0200}
}
EUVIMED